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ole of the Endothelium in
odulating Neointimal Formation
asculoprotective Approaches to Attenuate
estenosis After Percutaneous Coronary Interventions
icholas Kipshidze, MD, PHD, FACC,* George Dangas, MD, PHD, FACC,*
ykola Tsapenko, MD, PHD,§ Jeffrey Moses, MD, FACC,* Martin B. Leon, MD, FACC,*
ichael Kutryk, MD,† Patrick Serruys, MD, PHD, FACC‡
ronx and New York, New York; Toronto, Canada; and Rotterdam, The Netherlands
Restenosis at the site of an endoluminal procedure remains a significant problem in the
practice of interventional cardiology. We present current data on intimal hyperplasia, which
identify the major role of endothelial cells (ECs) in the development of restenosis.
Considering endothelial denudation as one of the most important mechanisms contributing
to restenosis, we focus more attention on methods of accelerating restoration of endothelial
continuity. Prevention of restenosis may be achieved by promoting endothelial regeneration
through the use of growth factors, EC seeding, vessel reconstruction with autologous
EC/fibrin matrix, and the use of estrogen-loaded stents and stents designed to capture
progenitor ECs. (J Am Coll Cardiol 2004;44:733–9) © 2004 by the American College of
Cardiology FoundationE
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tn recent decades, the number of coronary artery bypass
raft surgery procedures has slowly declined as a result of
ontinued conversion to percutaneous transluminal coronary
ngioplasty (PTCA) and stent implantation (1). The intro-
uction of stents has resulted in a significant decrease of
essel remodeling and elastic recoil at the site of interven-
ion and clearly has demonstrated the superiority of stent
mplantation to PTCA alone, with respect to restenosis in
e novo coronary lesions (2–4). However, it also is evident
hat neointimal proliferation is not affected by stenting
echniques (5). Unfortunately, this complication remains
ifficult to prevent and, regardless of the treatment strategy,
he rate of in-stent restenosis is still unacceptably high (20%
o 80% after bare-metal stent implantation) (2–4). The aim
f this review is to analyze the role of endothelium in the
estenotic process and to provide an update on experimental
nd clinical studies that use interventions designed to
romote vascular healing.
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ndothelial denudation is considered to be a primary injury
vent after balloon angioplasty and/or stent implantation
Fig. 1). Besides modulating local hemostasis and throm-
olysis, producing vasoactive compounds, and providing a
onpermeable barrier protecting smooth muscle cells
SMCs) against circulating growth-promoting factors, en-
othelial cells (ECs) produce a significant number of base-
ent membrane components and synthesize several growth
actors, including fibroblast growth factor, platelet-derived
rowth factor, and transforming growth factor-beta as well
s heparin and other growth-inhibitory factors that are
mportant in SMC proliferation. Endothelial cells may
hemselves maintain the mitogenic quiescence of SMCs by
he growth-inhibitory effect of nitric oxide (NO) (6). When
n a confluent monolayer, ECs cease replication. The
isruption of cell contact inhibition results in rapid EC
eplication from the proximal and distal untraumatized
egments. The SMCs proliferate and migrate to the de-
ndothelialized vessel surface, where they continue to pro-
iferate and secrete extracellular matrix proteins, leading to
eointimal tissue formation.
With denudation of a small area of the endothelial
urface, little to no intimal hyperplasia is observed (7,8).
hen larger areas are denuded, there is a greater degree
f intimal thickening (9). Focal fibrin deposition with
hrombus formation is universally observed within the
rst three days of stent implantation and is proportional
o the depth and extent of injury to the arterial wall.
nflammation accompanies vessel injury and attracts
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Endothelium in Restenosis After PCI August 18, 2004:733–9latelets and leucocytes that release growth factors and
ytokines (Fig. 2), which may initiate the activation of
MCs. It also was demonstrated that SMCs appear in
he intima only in areas that are not re-endothelialized
even days after injury (10). We also showed that more
evere and deeper injury to the vessel wall results in
elayed re-endothelization (Fig. 3).
Grewe et al. (11) described three phases of stent integra-
ion. In the acute phase (6 weeks), the border between the
ascular lumen and arterial wall is constituted by a thin,
ultilayered thrombus, and no ECs are found in the
mplantation zone. During the time course of integration,
ncreasing numbers of SMCs and amounts of extracellular
atrix can be detected. In the intermediate phase (6 to 12
eeks), the neointima consists of extracellular matrix and
ncreasing numbers of SMCs. Increasing numbers of
Cs are found on the luminal surface of the stent neoin-
ima. In the chronic phase (three months), complete re-
ndothelization is first noted. Matrix structures increase,
hereas the number of SMCs decreases. During all phases
f stent incorporation, the stent material is covered by a thin
roteinaceous layer.
A time-course analysis of stent endothelization in a rabbit
liac artery model disclosed 20% stent re-endothelization
t 4 days, 40% at 7 days, and near-complete endotheliza-
ion at 28 days after stent implantation (12). The time
ourse for re-endotheliization of the injured vessel has been
tudied in several other animal models with different types
f injuries with controversial results (Fig. 4), suggesting a
ultifactorial process.
Abbreviations and Acronyms
EC  endothelial cell
LPLI  low-power laser irradiation
NO  nitric oxide
PTCA  percutaneous transluminal coronary angioplasty
SMC  smooth muscle cell
VEGF  vascular endothelial growth factorFigure 1. Proposed mechanism of restenosis. sThe ECs can have heterotopic origins and supply sources.
n 1963, Stump et al. (13) provided evidence that ECs can
lso be derived from the peripheral blood. Further studies
onfirmed their origin from the hematopoietic stem cells
nd from hemangioblast precursor cells (14,15). Endothelial
rogenitor cells isolated from peripheral blood also can be
erived directly from monocytes/macrophages (16). There
s strong evidence that mature ECs that have a constant
upply of blood-borne multipotent endothelial-like cells can
ndergo transdifferentiation and serve as a potential source
f at least certain mesenchymal cells, including SMC (17).
The regenerating endothelium experiences long-term
3 months) dysfunction, characterized by decreased vas-
ular integrity and increased permeability. Dysfunction is
ore pronounced after stenting than after PTCA (18) and
lso is characterized by impaired endothelium-dependent
asodilatation. Influences that lead to increased intracellular
yclic adenosine monophosphate may promote re-
ndothelization, reduce endothelial permeability, and atten-
ate fibromuscular proliferation (19). In addition, intima
hat is affected by atherosclerosis contains ECs with lowered
yclic adenosine monophosphate content, which points to
imilarities in the development of both pathologic condi-
ions: restenosis and atherosclerosis. Thus, the re-
ndothelization of an injured vessel requires a long period of
ime; this delay could substantially contribute to restenosis.
igure 2. Impact of the stent implantation on the vessel wall. EC 
ndothelial cell.
igure 3. Relationship between severity of the vessel wall injury (by injury
core) and endothelial cell (EC) regeneration (%).
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August 18, 2004:733–9 Endothelium in Restenosis After PCIn theory, early confluent re-endothelialization by EC
eeding may reduce SMC proliferation, migration, or both.
The disruption of deeper vessel wall structures may lead
o the activation of other mechanisms involved in neointima
ormation (Fig. 5), pointing to its importance along with
e-endothelization in the development of vessel stenosis.
Besides playing a primary role in neointimal hyperplasia,
ontinuous inflammation may be an important factor in the
estenosis of stenting. Despite the many impacts of the
mplanted stent on the vessel wall, triggered inflammation
esponse is believed to be the factor responsible for more
evere intimal hyperplasia after stenting compared with
alloon angioplasty (5). Corrosion products of metallic
tents found in the subendothelial space at the site of stent
mplantation may be of great importance in this process.
urthermore, in some individuals, a contact allergy to
ertain metallic ions that are present in stainless-steel stents
e.g., nickel, chrome, molybdenum) may potentially trigger
xcessive intimal growth (20). There also is experimental
vidence that the degree of inflammation and subsequent
igure 4. Time course of endothelial cell regeneration after percutaneous
oronary interventions in different animal models.
igure 5. Severity of the vessel wall injury and activated mechanisms in the
amina.eointima formation is proportional to the degree of
enetration of the vessel wall by the stent struts (21).
ndothelial regeneration seems to be significantly dimin-
shed in the presence of metallic wires, causing delayed
e-endothelization of bare metallic stents (22). These prob-
ems are successfully being resolved by coating the stents
ith different polymers, which also provide a biologically
nert barrier between the stent surface, vascular tissues, and
irculating blood and can be a feasible platform for local
rug delivery, gene therapy, and recolonization of the stent
ith ECs.
NTERVENTIONS TO PROMOTE ENDOTHELIALIZATION
echanical approach. Numerous reports suggest that
ow-power laser irradiation (LPLI) is capable of affecting
ellular processes in the absence of significant thermal effect
23–25). We observed in vitro (26) that LPLI of vascular
nd cardiac cells results in a statistically significant increase
f vascular endothelial growth factor (VEGF) secretion in
ulture (1.6-fold for SMCs and fibroblasts; 7-fold for
ardiomyocytes). This effect was dose-dependent (maximal
ith LPLI of 0.5 J/cm2 for SMC, 2.1 J/cm2 for fibroblasts,
nd 1.05 J/cm2 for cardiomyocytes) and stimulated EC
rowth in culture. Further studies (27) showed that those
ffects were produced by inducible nitric oxide synthase
nduction and elevation of cyclic guanosine monophosphate
n cells treated by LPLI. These data may have significant
mportance in the development of new methods for endolu-
inal postangioplasty vascular repair and myocardial
hotoangiogenesis.
Intravascular sonotherapy has demonstrated its efficacy in
he prevention of neointimal hyperplasia after stent implan-
ation (28). In addition to its capability in decreasing cellular
roliferation (29), there is new evidence of a positive effect
f intravascular sonotherapy on cell recovery through the
pment of restenosis. EEL external elastic lamina; IEL internal elasticdevelo
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Endothelium in Restenosis After PCI August 18, 2004:733–9cceleration of microtubule and microfilament reassembly,
hich needs further investigation (P. Fitzgerald, personal
ommunication, 2002).
ocal delivery of growth factors. Studies of the use of
rowth factors to accelerate endothelialization have brought
ery interesting and controversial results. Callow et al. (30)
ound VEGF stimulated rabbit EC proliferation in vitro at
oncentrations of 100 ng/ml. However, it had no effect on
MC cell proliferation at concentrations up to 500 ng/ml.
ight weeks of administration resulted in 88.1  3.1%
e-endothelialization compared with controls (44.7  3.8%).
ence, VEGF appears to be a specific mitogen-inducing
ndothelial regeneration. Recently, Van Belle et al. (31,32)
emonstrated that local delivery of VEGF accelerates stent
ndothelialization and reduces stent thrombosis in a rabbit
odel. Vascular endothelial growth factor also augments NO
elease from the endothelium (33). However, while growth
actors increase the rate of endothelial regeneration, many of
hem are also potent mitogens for vascular smooth muscle cells.
ndeed, Moulton et al. (34) observed that prolonged treatment
ith the angiogenesis inhibitor endostatin or TNP-470 re-
uced plaque growth in mice.
ndothelial cell seeding. Previous attempts to seed ECs
sing a variety of delivery devices to the vascular wall have
een hampered by rapid loss of the seeded cells and also by
he difficulty of maintaining cell adherence to the vessel wall
hen blood flow is restored (35–39). Although the seeding
f ECs during or after coronary intervention is an attractive
oncept, major limitations include: 1) prolonged seeding
ime, 2) suboptimal delivery device, and 3) marginal adhe-
ion of a functional EC to the area of vascular injury. In
tudies on swine femoral arteries, Nabel et al. (36) achieved
% to 11% adherence of cells to the denuded arterial wall
fter 30 min of reseeding. Thompson et al. (37) have
chieved 36% EC attachment to damaged human saphe-
ous veins in vitro. The same investigators demonstrated
7% cell retention after 100 min of blood flow in previously
ngioplastied external iliac arteries of rabbits (38).
Nugent and Edelman (40) used EC implants grown in
olymer matrices for the control of vascular repair in a
orcine model of arterial injury. Porcine and bovine EC
mplants significantly reduced experimental restenosis three
onths after angioplasty compared with controls by 56%
nd 31%, respectively. No implanted cells or focal inflam-
atory reactions were detected histologically at any of the
mplant sites at 90 days. Allogeneic implants provide a
reater benefit than xenogeneic implants.
Conte et al. (39,41) have shown that autologous venous
ells can be genetically modified and returned to the surface
f a balloon-injured rabbit femoral artery. Vessels examined
t four to seven days after seeding displayed 40% to 90%
overage with transduced cells, even when seeded at sub-
onfluent density, and an intact EC monolayer, as evi-
enced by scanning electron microscopy studies. However,
heir method required surgical exposure of the vessels and
omplete interruption of blood flow for 30 min. bIt has been shown that ECs grow faster on surfaces
retreated with plasma proteins, especially those involved in
oagulation, because the fibronectin, fibrinogen, and vitro-
ectin contained in autologous cryoprecipitate preparations
ave specific binding sites for ECs (35,42). Recently,
odified autologous cryoprecipitate has become an impor-
ant reagent in the ongoing attempts to line the luminal
urface of vascular prosthesis with autologous ECs (43–45).
ur preliminary studies have confirmed that ECs remain
iable when attached to fibrin meshwork in a three-
imensional glue matrix. Furthermore, the non-cytotoxic
brin matrix meshwork is flexible and compliant and may be
asily adapted to a circumferential contour wall and timely
esorbed to leave a completely healed tissue. Areas occupied
y adherent ECs and cell-free areas that may serve as depots
or drug delivery characterize the structure.
We also applied an alternative technique for EC seeding
sing fibrin matrix and assessed the impact of this technique
n restenosis at eight weeks after balloon angioplasty in iliac
rteries of atherosclerotic rabbits (46). Histologic examina-
ion demonstrated the ability of this method to reattach the
C/fibrin matrix circumferentially to the denuded arterial
all segment and to significantly reduce restenosis. More-
ver, after reconstruction all vessels remained patent and
ppeared free of thrombosis on gross examination. This
esult was consistent with previous studies that showed EC
eeding also reduced platelet deposition in a canine endar-
erectomy model (32). Near-complete re-endothelialization
f treated arteries was explained by the observation that the
Cs from the border of denuded area then preferentially
igrate into this three-dimensional matrix structure (42).
orphometric analysis showed that the lumen area was
ignificantly greater in the EC/matrix group than in EC
eeding alone or in fibrin matrix alone.
In clinical settings, this process would require the patient
o be the autologous donor for the ECs and reagents for the
iologic matrix. Thus, the method has the advantage of
voiding potential immunologic/rejection problems. These
ata indicate that related plasma proteins are able to
erform some of the functions of the extracellular matrix
nvolved in anchoring ECs to the vessel wall. Therefore, the
oncept of reconstruction of the arterial wall with EC/fibrin
atrix to prevent restenosis remains appealing.
EALING-ENHANCING STENTS
ascular endothelial growth factor-eluting stents. De-
pite promising results with local delivery of the VEGF to
he site of vascular injury, a recently conducted experimental
tudy on VEGF-eluting stents failed to demonstrate a
eneficial effect on endothelization or on intimal hyperpla-
ia. These VEGF-eluting stents did not accelerate endothe-
ization or inhibit restenosis, but they did reduce the stent
hrombosis rate, which may make these stents less throm-
ogenic (47). Accelerated endothelialization by local deliv-
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August 18, 2004:733–9 Endothelium in Restenosis After PCIry of endothelial-specific growth factors could constitute an
ttractive alternative to direct antiproliferative strategies.
stradiol-eluting stents. Estradiol may improve vascular
ealing, reduce SMC migration and proliferation, and
romote local angiogenesis. Several animal and human
tudies have demonstrated a protective effect of estrogen on
oronary circulation (48–50). Estrogen appears not only to
ave a beneficial effect on lipids but also stimulates NO
roduction by ECs, as well as inhibiting the expression of
he proto-oncogene c-myc, which is implicated in the
evelopment of intimal hyperplasia (48,49). Estradiol may
lso contribute to vascular healing and to the prevention of
estenosis by improving re-endothelization (estrogen recep-
or alpha-activation) and by decreasing SMC migration and
roliferation (estrogen receptor beta-activation) (51). This
igure 6. Time course of endothelial progenitor cell (EPC) capture. (A) En
n peripheral blood at concentrations of 3 to 10 cells/mm3. (B) Anti-CD3
urface. (C) Over time, EPCs bound to the endoluminal surface of the ste
unctional endothelial cell monolayer on the stented arterial segment.
igure 7. In vivo endothelial progenitor cell (EPC) capture at 1 h after dep
A to C) anti-CD34-coated stents. (D to F) bare stainless-steel stents. (A
rterial segments. (B) and (E), high-magnification scanning electron m
mmunohistochemical staining for the endothelial cell (EC) marker (ulex eu
nuclear marker that stains all cells red. All EC marker-positive cells appeoverage with EC marker-positive cells 1 h after stent deployment. Stainless-stxplains why 17-beta-estradiol–eluting stents are associated
ith reduced neointimal formation without affecting endo-
helial regeneration with potential benefit in the prevention
nd treatment of in-stent restenosis (50). Recent data have
hown that estradiol-eluting phosphorylcholine-coated
tents that are implanted in porcine coronary arteries re-
uced neointimal hyperplasia by 40% compared with con-
rol stents.
The Estrogen And Stent To Eliminate Restenosis (EAS-
ER) study was a single-center feasibility study testing
7-beta-estradiol– eluting BiodivYsio (Abbott, Abbott
ark, Illinois) stents in 30 patients with de novo coronary
esions. Stents were loaded on-site by immersion in a
olution of estradiol. Late loss was 0.32 mm in lesion and
.57 mm in stent. Neointimal hyperplasia, detected using
elial progenitor cells originate in the bone marrow and circulate postnatally
body-coated stents, once deployed, have the ability to bind EPCs to their
oliferate and migrate to fill the intra strut spaces establishing a confluent,
nt. All stents were deployed into the coronary arteries of Yorkshire Swine.
(D), low-magnification scanning electron micrographs (220) of stented
raphs (2,500). (C) and (F), Confocol microscopy images (200) of
us agglutinin 1). Cells were counted after staining with propidium iodine,
en/yellow. Anti-CD34 antibody-coated stents showed 70% cell surfacedoth
4 anti
nt prloyme
) and
icrog
ropae
ar greeel stents showed little to no cell coverage after 1 h.
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Endothelium in Restenosis After PCI August 18, 2004:733–9ntravascular ultrasonography, was 23.5%. At six months,
here were no deaths or stent thromboses, and only one
atient underwent repeat revascularization. A second phase
f the EASTER study has recently concluded, and results
re pending.
tents attracting ECs. Stents may be used to attract
irculating ECs. R stents (Orbus Medical Technologies,
ort Lauderdale, Florida) coated with antibodies to CD34
eceptors on progenitor circulating ECs have been im-
lanted in pig coronary arteries. Preliminary results suggest
he feasibility of capturing ECs in situ (M. Kutryk, unpub-
ished data, 2002) (Figs. 6 and 7). These nondrug-eluting
tents would ultimately promote the elution of biologically
ctive substances through a functioning endothelium mono-
ayer. The effects of these novel stents on restenosis remain
o be demonstrated.
Kutryk et al. (52) proposed the seeding of intravascular
tents by the xenotransplantation of genetically modified
Cs, which were capable of modifying the pathophysiologic
esponse to vessel wall damage and provide controllable
evels of active compounds. The feasibility and potential of
his method has been demonstrated in animal studies. There
re also preliminary data (53) suggesting that endoluminal
eeding of syngeneic SMCs can be effective in reducing
ntimal hyperplasia in a restenosis animal model and in
rterial allografts.
onclusions. Endothelial denudation and dysfunction are
ommon at the site of endovascular interventions and have
een associated with vessel thrombosis and restenosis. In
ddition, delayed re-endothelialization has been associated
ith late side effects of potent antiproliferative therapies,
uch as with radiation therapy. The promotion of healing in
he vascular endothelium may be a more natural and
onsequently safer approach in the prevention of restenosis.
One of the future approaches to overcoming the re-
tenosis problem is promoting and accelerating re-
ndothelialization in the injured vessel. Along with using
rowth factors to enhance endothelial regeneration, EC
eeding, vascular reconstruction using autologous EC/fibrin
atrix, vasculoprotective compound-eluting stents, and
C-capture stents may have substantial potential in pre-
enting restenosis. Despite the obvious benefit of interven-
ions that promote the endothelization of stents, the clinical
eduction of restenosis still remains to be proved. Further
xploration into the control mechanism of the endothelium
unction and interaction with surrounding tissues, as well as
linical trials, would provide additional insight and support
f this novel approach in the treatment of restenosis.
eprint requests and correspondence: Dr. Nicholas Kipshidze,
enox Hill Heart and Vascular Institute, 130 East 77th Street,
ew York, New York 10021. E-mail: NKipshidze@Lenoxhill.net.
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